Quantcast

Latest Quanterix Corporation Stories

2011-08-16 07:00:00

CAMBRIDGE, Mass. and BIRKENFELD, Germany, Aug. 16, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA(TM)) technology, and STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX), a worldwide leader in the development and manufacture of automated analyzer systems, today announced an agreement to co-develop and manufacture a fully-automated instrument for Quanterix's...

2011-07-21 08:00:00

CAMBRIDGE, Mass., July 21, 2011 /PRNewswire/ -- Quanterix Corporation, an in-vitro diagnostics (IVD) company providing life science researchers and IVD labs single molecule technology with unprecedented sensitivity and precision, announced that the analytical performance of AccuPSA(TM), a fifth-generation digital immunoassay for Prostate Specific Antigen (PSA), demonstrated a robust 2-log improvement in sensitivity over today's ultrasensitive third-generation assays for measuring PSA in...

2011-07-20 07:00:00

CAMBRIDGE, Mass. and SALZBURG, Austria, July 20, 2011 /PRNewswire/ -- Quanterix Corporation, enabling a new generation of diagnostic tests based on the revolutionary Single Molecule Array (SiMoA(TM)) technology, and Sony DADC Austria AG, today announced that they have entered into a collaboration for the development and manufacture of "smart consumables" for use in the life science and in vitro diagnostic (IVD) markets. Production of the Quanterix SiMoA Disc marks the first diagnostic...

2011-04-12 12:30:00

CAMBRIDGE, Mass., April 12, 2011 /PRNewswire/ -- Quanterix Corporation, enabling a new generation of diagnostics based on revolutionary Single Molecule Array (SiMoA(TM)) technology, today announced that significant elevations in blood levels of amyloid beta (Abeta) 42 peptide, a component of the plaques that are a hallmark of Alzheimer's disease, were detected in patients who experienced hypoxia (inadequate supply of oxygen to the brain) following cardiac arrest. The ability of SiMoA to...

2011-02-23 09:38:00

CAMBRIDGE, Mass., Feb. 23, 2011 /PRNewswire/ -- Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company's Single Molecule Array (SiMoA(TM)) technology by combining digital and analog detection in one straightforward measurement. The article appears in the journal Analytical Chemistry, and highlights...

2011-02-22 06:30:00

CAMBRIDGE, Mass., Feb. 22, 2011 /PRNewswire/ -- Quanterix Corporation, enabling a new generation of diagnostic tests based on revolutionary Single Molecule Array (SiMoA(TM)) technology, today announced that it has entered into an evaluation agreement with Novartis Diagnostics on the potential use of Quanterix's SiMoA platform technology for diagnostic use. The evaluation will be conducted at Quanterix and will focus on an undisclosed neuron-specific protein target. "We are excited to...

2010-12-01 07:30:00

CAMBRIDGE, Mass., Dec. 1, 2010 /PRNewswire/ -- Quanterix Corporation announced today that Martin D. Madaus, Ph.D has joined the company's Board as Executive Chairman. Dr. Madaus brings more than 20 years of experience in the diagnostics and life science industries, most recently serving as President, Chairman and CEO of Millipore Corporation, recently acquired by Merck KGaA. "Martin brings significant expertise, both strategic and commercial, that will be invaluable to Quanterix as we...

2010-11-02 11:26:00

CAMBRIDGE, Mass., Nov. 2, 2010 /PRNewswire/ -- Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program recognized Quanterix's Single Molecule Array (SiMoA(TM)) platform as a promising advance that will improve diagnosis and treatment of disease while reducing healthcare costs....

2010-05-23 12:00:00

CAMBRIDGE, Mass., May 23 /PRNewswire/ -- Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence. The research article, featured on the cover of the June issue (Volume 28, No. 6) of Nature Biotechnology, describes how...

2009-09-02 08:00:00

CAMBRIDGE, Mass., Sept. 2 /PRNewswire/ -- Quanterix Corporation, the leader in single molecule detection, announced today that David Okrongly, Ph.D. has been appointed Chief Executive Officer and a member of the company's Board of Directors. Dr. Okrongly replaces co-founder and interim CEO, Nicholas Naclerio, Ph.D., who will continue serving as Chairman of the Board. Dr. Okrongly joins Quanterix from Siemens Healthcare Diagnostics Division, where he most recently served as Senior Vice...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related